stockportfolio.pro
Insmed Incorporated (INSM)
Healthcare · Biotechnology · NasdaqGS
Insmed Incorporated revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $9.84M | $136.47M | $164.41M | $188.46M | $245.36M | $305.21M | $363.71M | $606.42M |
| Gross profit | — | — | $7.41M | $112.25M | $124.54M | $144.31M | $190.23M | $239.63M | $277.96M | $483.49M |
| Net income | $-176.27M | $-192.65M | $-324.28M | $-254.34M | $-294.09M | $-434.65M | $-481.53M | $-749.57M | $-913.77M | $-1.28B |
| Net margin | — | — | -3297.2% | -186.4% | -178.9% | -230.6% | -196.3% | -245.6% | -251.2% | -210.5% |
Source: Insmed Incorporated SEC filings (10-K). 17 years of history available in the interactive view.
Explore 17 years of Insmed Incorporated financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track INSM in your portfolio →
Insmed Incorporated financial history by metric
About Insmed Incorporated
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Insmed Incorporated — frequently asked questions
What is Insmed Incorporated's revenue?
Insmed Incorporated (INSM) reported revenue of $606.42M for fiscal year 2025, up 66.7% from the prior year, according to its SEC filings.
Is Insmed Incorporated profitable?
No — INSM reported a net loss of $-1.28B in fiscal 2025.
What is INSM's P/E ratio?
Insmed Incorporated trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Insmed Incorporated growing?
INSM's revenue grew at roughly 29.8% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Insmed Incorporated have?
As of fiscal year 2025, INSM carried roughly $540.96M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Insmed Incorporated's gross margin?
INSM's gross margin was 79.7% in fiscal 2025 — gross profit of $483.49M on revenue of $606.42M.
What is Insmed Incorporated's market cap?
Insmed Incorporated (INSM) has a market capitalization of about $20.94B, based on the latest data in our nightly-refreshed cache.
When does Insmed Incorporated's fiscal year end?
INSM's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Insmed Incorporated's official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.